J Korean Med Sci.  2024 Apr;39(15):e146. 10.3346/jkms.2024.39.e146.

Interim Estimates of 2023–2024 Seasonal Influenza Vaccine Effectiveness Among Adults in Korea

Affiliations
  • 1Division of Infectious Diseases, Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea
  • 2Vaccine Innovation Center-KU Medicine (VIC-K), Seoul, Korea
  • 3Division of Infectious Diseases, Department of Internal Medicine, St. Vincent’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea
  • 4Division of Infectious Diseases, Department of Internal Medicine, Kangnam Sacred Heart Hospital, Hallym University College of Medicine, Seoul, Korea
  • 5Division of Infectious Diseases, Department of Internal Medicine, Inha University School of Medicine, Incheon, Korea
  • 6Devision of Infectious Disease, Department of Internal Medicine, Chungbuk National University College of Medicine, Cheongju, Korea
  • 7Division of Infectious Diseases, Department of Internal Medicine, Gil Medical Center, Gachon University College of Medicine, Incheon, Korea

Abstract

In the 2023–2024 season, the influenza epidemic in South Korea peaked earlier than in recent years. In this study, we aimed to estimate the interim vaccine effectiveness (VE) of the influenza vaccination to prevent influenza during the early season. From November 1, 2023, to December 31, 2023, we enrolled 2,632 subjects with influenza-like illness from eight hospitals participating in hospital-based influenza morbidity and mortality surveillance. A retrospective test-negative case-control study was conducted to estimate the VE. The results showed an adjusted VE of 22.5% (95% confidence interval [CI], 6.6 to 35.8) for the total population. The adjusted VE was 22.3% (95% CI, 6.1 to 35.7) for influenza A and 9.4% (95% CI, −51.3 to 45.7) for influenza A/H1N1. Full results of the analysis will be reported.

Keyword

Influenza; Influenza Vaccine; Vaccination; Vaccine Effectiveness

Reference

1. Korea Disease Control and Prevention Agency. Influenza epidemic warning issued for the 2023–2024 season. Updated 2023. Accessed January 24, 2024. https://www.kdca.go.kr/board/board.es?mid=a20501010000&bid=0015&act=view&list_no=723470 .
2. Korea Disease Control and Prevention Agency. Surveillance statistics of infectious disease for week 1, 2024. Updated 2024. Accessed February 20, 2024. https://www.phwr.org/journal/archives_Supple_View.html?eid=U3VwcGxlX251bT01OQ== .
3. Chung JR, Kim SS, Kondor RJ, Smith C, Budd AP, Tartof SY, et al. Interim estimates of 2021–22 seasonal influenza vaccine effectiveness—United States, February 2022. MMWR Morb Mortal Wkly Rep. 2022; 71(10):365–370. PMID: 35271561.
4. McLean HQ, Petrie JG, Hanson KE, Meece JK, Rolfes MA, Sylvester GC, et al. Interim estimates of 2022–23 seasonal influenza vaccine effectiveness - Wisconsin, October 2022-February 2023. MMWR Morb Mortal Wkly Rep. 2023; 72(8):201–205. PMID: 36821715.
5. Price AM, Flannery B, Talbot HK, Grijalva CG, Wernli KJ, Phillips CH, et al. Influenza vaccine effectiveness against influenza A (H3N2)-related illness in the United States during the 2021–2022 influenza season. Clin Infect Dis. 2023; 76(8):1358–1363. PMID: 36504336.
6. Domnich A, Orsi A, Ogliastro M, Trombetta CS, Scarpaleggia M, Stefanelli F, et al. Influenza vaccine effectiveness in preventing hospital encounters for laboratory-confirmed infection among Italian adults, 2022/23 season. Vaccine. 2023; 41(33):4861–4866. PMID: 37385889.
7. Maurel M, Howard J, Kissling E, Pozo F, Pérez-Gimeno G, Buda S, et al. European IVE group. Interim 2023/24 influenza A vaccine effectiveness: VEBIS European primary care and hospital multicentre studies, September 2023 to January 2024. Euro Surveill. 2024; 29(8):2400089. PMID: 38390651.
8. Korea Disease Control and Prevention Agency. Guidelines for the management of Influenza for the 2023–2024 season. Accessed January 24, 2024. https://www.kdca.go.kr/board/board.es?mid=a20507020000&bid=0019 .
9. Paules CI, Sullivan SG, Subbarao K, Fauci AS. Chasing seasonal influenza—the need for a universal influenza vaccine. N Engl J Med. 2018; 378(1):7–9. PMID: 29185857.
10. Okoli GN, Racovitan F, Abdulwahid T, Righolt CH, Mahmud SM. Variable seasonal influenza vaccine effectiveness across geographical regions, age groups and levels of vaccine antigenic similarity with circulating virus strains: a systematic review and meta-analysis of the evidence from test-negative design studies after the 2009/10 influenza pandemic. Vaccine. 2021; 39(8):1225–1240. PMID: 33494964.
11. Korea Disease Control and Prevention Agency. Increase in type B influenza epidemic, hurry up for influenza vaccination now. Updated 2024. Accessed February 20, 2024. https://www.kdca.go.kr/board/board.es?mid=a20501010000&bid=0015&list_no=724495&cg_code=&act=view&nPage=3 .
Full Text Links
  • JKMS
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr